Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | SLC34A1 | Q06495 | 4/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726063 | 0.93 | HSD11B1 (0.40) | HSD11B1P2RX7CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL173227 | 0.89 | HSD11B1 (0.38) | HSD11B1P2RX7CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1725413 | 0.88 | HSD11B1 (0.39) | HSD11B1P2RX7CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL671697 | 0.87 | HSD11B1 (0.40) | HSD11B1P2RX7CYP3A4PTPN11PGR | |
| SCHEMBL671108 | 0.87 | HSD11B1 (0.40) | HSD11B1P2RX7CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1725409 | 0.86 | HSD11B1 (0.39) | HSD11B1P2RX7CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL672551 | 0.86 | HSD11B1 (0.39) | HSD11B1P2RX7CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL20680789 | 0.84 | HSD11B1 (0.41) | HSD11B1P2RX7IGF1R | |
| SCHEMBL14990292 | 0.84 | HSD11B1 (0.39) | HSD11B1P2RX7CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL15952664 | 0.82 | CES2 (0.33) | CYP3A4CYP1A2CYP2C9CYP2C19PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170223959-A1 | FUNGICIDAL PYRAZOLES | FMC CORPORATION | 2017-08-10 | — | — | US | claimed |
| US-20170150719-A1 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | FMC CORPORATION | 2017-06-01 | — | — | US | claimed |
| EP-2966063-A1 | FUNGICIDAL PYRAZOLES | E. I. du Pont de Nemours and Company (US) | 2016-01-13 | — | — | EP | claimed |
| US-20150305339-A1 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | FMC CORPORATION | 2015-10-29 | — | — | US | claimed |
| US-20150230467-A1 | FUNGICIDAL PYRAZOLES | FMC CORPORATION | 2015-08-20 | — | — | US | claimed |
| US-20130129839-A1 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-05-23 | — | — | US | claimed |
| US-20110319430-A1 | FUNGICIDAL PYRAZOLES | E.I. DU PONT NEMOURS AND COMPANY (US) | 2011-12-29 | — | — | US | claimed |
| EP-3590340-B1 | INTERMEDIATES FOR THE SYNTHESIS OF FUNGICIDAL PYRAZOLES | FMC CORP (US) | 2023-11-15 | — | — | EP | disclosed |
| US-10448639-B2 | Fungicidal pyrazoles | FMC CORPORATION (US) | 2019-10-22 | — | — | US | disclosed |
| US-20170223959-A1 | FUNGICIDAL PYRAZOLES | FMC CORPORATION | 2017-08-10 | — | — | US | disclosed |
| US-20170150719-A1 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | FMC CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-9655361-B2 | Fungicidal pyrazoles | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9596853-B2 | Fungicidal pyrazoles and their mixtures | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20130123323-A1 | FUNGICIDAL PYRAZOLES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2012031061-A2 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012024586-A1 | FUNGICIDAL PYRAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012023143-A1 | FUNGICIDAL PYRAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
| EP-2403834-A1 | Fungicidal pyrazoles | E. I. du Pont de Nemours and Company (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319430-A1 | FUNGICIDAL PYRAZOLES | E.I. DU PONT NEMOURS AND COMPANY (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010101973-A1 | FUNGICIDAL PYRAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319430-A1 | FUNGICIDAL PYRAZOLES | CBR3, CBR1, CYP2S1 | HSD11B1 962/4885P2RX7 1017/4885CYP3A4 6/4885 |
| US-20130129839-A1 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | CYP1B1, NOX3, NOX1 | HSD11B1 1540/4885P2RX7 710/4885CYP3A4 36/4885 |
| US-20150305339-A1 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | CYP1B1, NOX3, NOX1 | HSD11B1 1540/4885P2RX7 710/4885CYP3A4 36/4885 |
| US-10448639-B2 | Fungicidal pyrazoles | CBR3, CBR1, CYP2S1 | HSD11B1 962/4885P2RX7 1017/4885CYP3A4 6/4885 |
| US-20150230467-A1 | FUNGICIDAL PYRAZOLES | CBR3, CBR1, CYP2S1 | HSD11B1 962/4885P2RX7 1017/4885CYP3A4 6/4885 |
| US-20130123323-A1 | FUNGICIDAL PYRAZOLES | CBR3, CYP1A1, CYP1B1 | HSD11B1 788/4885P2RX7 517/4885CYP3A4 9/4885 |
| US-20170150719-A1 | FUNGICIDAL PYRAZOLES AND THEIR MIXTURES | CYP1B1, NOX3, NOX1 | HSD11B1 1540/4885P2RX7 710/4885CYP3A4 36/4885 |
| US-20170223959-A1 | FUNGICIDAL PYRAZOLES | CBR3, CBR1, CYP2S1 | HSD11B1 962/4885P2RX7 1017/4885CYP3A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.